Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural r… Read more
Market Cap & Net Worth: Integra LifeSciences Holdings (IART)
Integra LifeSciences Holdings (NASDAQ:IART) has a market capitalization of $693.24 Million ($693.24 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10052 globally and #4704 in its home market, demonstrating a -6.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Integra LifeSciences Holdings's stock price $8.90 by its total outstanding shares 77892111 (77.89 Million).
Integra LifeSciences Holdings Market Cap History: 2015 to 2026
Integra LifeSciences Holdings's market capitalization history from 2015 to 2026. Data shows change from $2.64 Billion to $693.24 Million (-11.15% CAGR).
Index Memberships
Integra LifeSciences Holdings is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.02% | #275 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #1039 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.35 Trillion | 0.10% | #513 of 602 |
Weight: Integra LifeSciences Holdings's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Integra LifeSciences Holdings Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Integra LifeSciences Holdings's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.10x
Integra LifeSciences Holdings's market cap is 1.10 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.64 Billion | $882.73 Million | -$3.52 Million | 2.99x | N/A |
| 2016 | $3.34 Billion | $992.08 Million | $74.56 Million | 3.37x | 44.81x |
| 2017 | $3.73 Billion | $1.19 Billion | $64.74 Million | 3.14x | 57.58x |
| 2018 | $3.51 Billion | $1.47 Billion | $60.80 Million | 2.39x | 57.78x |
| 2019 | $4.54 Billion | $1.52 Billion | $50.20 Million | 2.99x | 90.43x |
| 2020 | $5.06 Billion | $1.37 Billion | $133.89 Million | 3.69x | 37.77x |
| 2021 | $5.22 Billion | $1.54 Billion | $169.07 Million | 3.38x | 30.86x |
| 2022 | $4.37 Billion | $1.56 Billion | $180.55 Million | 2.80x | 24.19x |
| 2023 | $3.39 Billion | $1.54 Billion | $67.74 Million | 2.20x | 50.08x |
| 2024 | $1.77 Billion | $1.61 Billion | -$6.94 Million | 1.10x | N/A |
Competitor Companies of IART by Market Capitalization
Companies near Integra LifeSciences Holdings in the global market cap rankings as of March 19, 2026.
Key companies related to Integra LifeSciences Holdings by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #84 globally with a market cap of $187.53 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #151 globally with a market cap of $119.88 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #170 globally with a market cap of $111.60 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #183 globally with a market cap of $105.38 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Abbott Laboratories | NYSE:ABT | $187.53 Billion | $108.49 |
| #151 | Stryker Corporation | NYSE:SYK | $119.88 Billion | $345.81 |
| #170 | Medtronic PLC | NYSE:MDT | $111.60 Billion | $87.21 |
| #183 | Boston Scientific Corp | NYSE:BSX | $105.38 Billion | $71.28 |
Integra LifeSciences Holdings Historical Marketcap From 2015 to 2026
Between 2015 and today, Integra LifeSciences Holdings's market cap moved from $2.64 Billion to $ 693.24 Million, with a yearly change of -11.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $693.24 Million | -28.34% |
| 2025 | $967.42 Million | -45.24% |
| 2024 | $1.77 Billion | -47.92% |
| 2023 | $3.39 Billion | -22.33% |
| 2022 | $4.37 Billion | -16.30% |
| 2021 | $5.22 Billion | +3.19% |
| 2020 | $5.06 Billion | +11.39% |
| 2019 | $4.54 Billion | +29.22% |
| 2018 | $3.51 Billion | -5.77% |
| 2017 | $3.73 Billion | +11.57% |
| 2016 | $3.34 Billion | +26.57% |
| 2015 | $2.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Integra LifeSciences Holdings was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $693.24 Million USD |
| MoneyControl | $693.24 Million USD |
| MarketWatch | $693.24 Million USD |
| marketcap.company | $693.24 Million USD |
| Reuters | $693.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.